PMID- 22465680
OWN - NLM
STAT- MEDLINE
DCOM- 20121010
LR  - 20120608
IS  - 1878-5891 (Electronic)
IS  - 0378-5955 (Linking)
VI  - 288
IP  - 1-2
DP  - 2012 Jun
TI  - Neurotrophins and their role in the cochlea.
PG  - 19-33
LID - 10.1016/j.heares.2012.03.002 [doi]
AB  - Spiral ganglion cell (SGC) degeneration following hair cell loss can be prevented 
      by administration of exogenous neurotrophic factors. Many of these neurotrophic 
      factors, in particular the neurotrophins brain-derived neurotrophic factor (BDNF) 
      and neurotrophin-3 (NT-3), have been described to be involved in the development 
      of the rodent cochlea. While expression of most of the neurotrophins has 
      decreased to below detectable levels during adulthood (only NT-3 remains highly 
      expressed), their respective receptors remain present in SGCs. Indeed much less 
      is known about the function of neurotrophins in the mature cochlea. Such 
      knowledge is crucial in the search for tools to improve SGC survival following 
      cochlear implantation. In this review, we will critically regard the current 
      experimental findings of neurotrophic treatment of the SGCs in the perspective of 
      fundamental cellular mechanisms underlying neurotrophin signaling. We conclude 
      that, in order to fully apprehend the effects of neurotrophic treatment of 
      degenerating SGCs and in order to consider clinical application of neurotrophins, 
      future research should focus (a) on characterizing the expression pattern of 
      neurotrophins in the cochlea after deafening, (b) on more detailed 
      characterization of functional and morphological changes of SGCs associated with 
      both deafening and neurotrophic treatment and (c) on the possible self-supporting 
      state of SGCs after cessation of short-term neurotrophic treatment.
CI  - Copyright (c) 2012 Elsevier B.V. All rights reserved.
FAU - Ramekers, Dyan
AU  - Ramekers D
AD  - Department of Otorhinolaryngology and Head & Neck Surgery, Rudolf Magnus 
      Institute of Neuroscience, University Medical Center Utrecht, Room G.02.531, P.O. 
      Box 85500, 3508 GA Utrecht, The Netherlands.
FAU - Versnel, Huib
AU  - Versnel H
FAU - Grolman, Wilko
AU  - Grolman W
FAU - Klis, Sjaak F L
AU  - Klis SF
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120321
PL  - Netherlands
TA  - Hear Res
JT  - Hearing research
JID - 7900445
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Receptors, Nerve Growth Factor)
SB  - IM
MH  - Animals
MH  - Auditory Pathways/metabolism
MH  - Cochlea/drug effects/*metabolism/pathology
MH  - Hearing Loss/drug therapy/metabolism/pathology
MH  - Humans
MH  - Nerve Growth Factors/*metabolism/therapeutic use
MH  - Neuroprotective Agents/therapeutic use
MH  - Receptors, Nerve Growth Factor/metabolism
MH  - *Signal Transduction/drug effects
MH  - Spiral Ganglion/metabolism/pathology
EDAT- 2012/04/03 06:00
MHDA- 2012/10/12 06:00
CRDT- 2012/04/03 06:00
PHST- 2011/12/14 00:00 [received]
PHST- 2012/02/10 00:00 [revised]
PHST- 2012/03/05 00:00 [accepted]
PHST- 2012/04/03 06:00 [entrez]
PHST- 2012/04/03 06:00 [pubmed]
PHST- 2012/10/12 06:00 [medline]
AID - S0378-5955(12)00059-7 [pii]
AID - 10.1016/j.heares.2012.03.002 [doi]
PST - ppublish
SO  - Hear Res. 2012 Jun;288(1-2):19-33. doi: 10.1016/j.heares.2012.03.002. Epub 2012 
      Mar 21.